Opioid Addiction Medication Not Offered in Most Residential Treatment Facilities

    Just 29% of residential treatment facilities in the United States offer the opioid addiction medication buprenorphine, a new study finds. An additional 21% of treatment centers discourage its use, according to a survey of 368 programs.

    The study, published in JAMA, used “secret shoppers” posing as uninsured 27-year-olds who used heroin. They called both private and government-run addiction treatment facilities.

    Lead author Dr. Michael Barnett of Harvard University’s Chan School of Public Health said buprenorphine should be a basic part of addiction treatment. “That’s a very low bar to pass and still most facilities aren’t meeting it,” he told WBUR. “As a physician, I’ve seen how medications like buprenorphine can let my patients with an addiction really lead normal lives. It’s a medication just like anything else we use to treat an illness, whether we use an antidepressant for someone who has depression or insulin for someone who has diabetes.”

    By Partnership Staff
    September 2020

    Published

    September 2020

    We use cookies to improve your experience and serve you relevant information. To learn more, read our privacy policy.